Royalty Pharma RPRX 深 沪
等待开盘 08-10 09:30:00 美东时间
56.77
-0.490
-0.86%
华盛通- 最 高59.6295
- 今 开57.44
- 成交量 364.55万股
- 最 低 56.36
- 昨 收 57.26
- 总市值 2469.50万
- 52周最高 60.44
- 市盈率 静 38.00
- 换手率 838.04%
- 52周最低 34.0805
- 委 比 92.54%
- 总股本 0.00亿
- 历史最高 60.44
- 量 比 1.14
- 振 幅 5.71%
- 历史最低 1.10
- 每 手 1
- 风险率 7.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
07-08 02:21
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
06-29 21:20
Royalty Pharma's Earnings: A Preview
Royalty Pharma (NASDAQ:RPRX) is preparing to release its quarterly earnings on ...
02-10 23:01
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.
01-13 01:26
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additional studies requested. Minimal delays expected.
2025-12-06 00:49
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Royalty Pharma将参加高盛第46届全球医疗健康大会，并进行网络直播。公司专注于生物制药特许权收购和创新资助，拥有多个知名产品的特许权组合。
2025-06-04 20:15
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
2024-09-19 01:35
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago. Results in the quarter were primarily impacted by a negative adjustment to prior periods' estimat...
2024-09-04 21:09
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement
05:49 PM EDT, 09/03/2024 (MT Newswires) -- Royalty Pharma plc (RPRX) entered into a $150 million capped synthetic royalty funding agreement with an Ascendis Pharma (ASND) unit. The Ascendis Pharma Bone Diseases subsidiary will get an upfront payment of $150 million in exchange for a 3% royalty on US...
2024-09-04 05:49
